Actavis Reaches Deal With Vivus Over Obesity Drug Patents
Vivus Inc. said Wednesday it reached a deal to end its patent suit against Teva Pharmaceuticals Inc. unit Actavis over its formula for obesity treatment drug Qsymia, closing a three-year row...To view the full article, register now.
Already a subscriber? Click here to view full article